Acessa Procedure Now Available to 20 Million More Women as a Result of Medicaid Programs Adding Coverage
More than 70 Million covered women now have access to the most comprehensive uterine fibroid treatment option with the least invasive technique
Despite this substantial momentum of insurance coverage, inconsistencies in benefit administration continue across the country. Today, most state Medicaid programs are administered by large, for-profit insurance carriers. As an example of the significant inconsistency in patients’ access to care, a Medicaid patient in
“The expansion of Medicaid coverage for the Acessa procedure represents another significant step forward in terms of recognizing the medical necessity of this procedure as well as increasing the number of options women have as alternatives to hysterectomy,” said
Hysterectomy is the second most common surgery performed on reproductive-aged women and continues to be the primary treatment for women with uterine fibroids in
The Acessa procedure is a minimally invasive, uterine sparing alternative option to hysterectomy. Acessa can treat almost all sizes and locations of fibroids, including those within the uterine walls. The procedure requires no cutting or suturing of uterine tissue, and patients typically go home the same day and have been shown to return to work and normal function within three to five days.
About the Acessa System
The Acessa System is the only radiofrequency ablation system cleared by the
About Acessa Health Inc.
Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation for the treatment of uterine fibroids and is continuing to develop technologies that improve the lives of its patients. Acessa Health’s headquarters are in
1 Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-7.
2 Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol. 2013;209(4):319 e1- e20.
3 Cardozo ER, Clark AD,
4 Corona LE, Swenson CW, Sheetz KH, et al. Use of other treatments before hysterectomy for benign conditions in a statewide hospital collaborative. American journal of obstetrics and gynecology. 2015 Mar;212(3):304, e301–307
5 Gingold JA,
View source version on businesswire.com: http://www.businesswire.com/news/home/20180213005526/en/
[email protected]
Source:
Brown & Brown, Inc. Recognized for Contribution to the American Red Cross Annual Disaster Giving Program
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News